Valneva shares tumble after suspension of US chikungunya vaccine licence

Valneva shares plunged over 20% following the U.S. FDA's immediate suspension of its chikungunya vaccine, Ixchiq, due to serious safety concerns, including 21 hospitalizations and three deaths with one fatality linked to vaccine-derived encephalitis, as the agency determined the vaccine's risks outweighed its benefits. The suspension impacts a product that contributed 8% of Valneva's H1 2025 product sales, prompting the company to halt U.S. sales, though it maintained its financial outlook. This action leaves Bavarian Nordic's Vimkunya as the sole chikungunya vaccine available in the U.S., while brokerage Kempen viewed Valneva's share price drop as an attractive entry point despite the setback.

Analysis

Valneva's stock plummeted over 20% after the U.S. FDA's immediate suspension of its chikungunya vaccine, Ixchiq, citing critical safety concerns. The regulatory action was based on more than 20 serious adverse events, including 21 hospitalizations and three deaths, with one fatality directly linked to the vaccine, leading the FDA's Center for Biologics Evaluation and Research to conclude that the vaccine's risks outweigh its benefits. The suspended product accounted for 7.5 million euros, over 8% of Valneva's total product sales in the first half of 2025, prompting an immediate halt to U.S. sales. Despite this significant setback, Valneva has not altered its financial outlook. The suspension leaves competitor Bavarian Nordic's Vimkunya as the sole remaining chikungunya vaccine in the U.S. market, creating a significant competitive advantage. In a contrarian note, brokerage Kempen viewed the sharp sell-off as an 'attractive entry point,' suggesting Ixchiq was a minor factor in the company's overall investment case.

Key Decisions for Investors

• Investors in Valneva should monitor for any potential downward revisions to its financial outlook, as the loss of Ixchiq revenue and significant reputational damage from the FDA's safety ruling present material headwinds.
• Consider the bullish implications for Bavarian Nordic, which now holds a monopoly in the U.S. chikungunya vaccine market, creating a clear path for increased market share and revenue acceleration.
• The starkly divergent fortunes of the two companies suggest that a pairs trade, long Bavarian Nordic (BAVA) and short Valneva (VALN), could be considered to capitalize on this direct transfer of market opportunity.